Corbus Pharmaceuticals Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Norwood MA United States (2009)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02466243
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Corbus Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

lenabasum (3 trials)

Drugs in Phase 2 Trials (1)

jbt-101 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Dermatomyositis (Phase 3)

Fibrosis (Phase 2)

Scleroderma, Diffuse (Phase 3)

Scleroderma, Systemic (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2